News & Updates

Show Multimedia Only

PCV21 shows promise as alternative to PCV13 for infants

23 Oct 2025 by

Three formulations of the 21-valent pneumococcal conjugate vaccine (PCV21) have shown favourable immunogenicity and acceptable tolerability profile among toddlers and infants, when compared with PCV13, in a phase II study.

PCV21 shows promise as alternative to PCV13 for infants

23 Oct 2025

Pooled data support ruxolitinib cream for treating prurigo nodularis

23 Oct 2025 by

Twice-daily application of ruxolitinib cream led to early and sustained improvement in the signs and symptoms of prurigo nodularis in adults, according to the pooled phase III TRuE-PN1 and TRuE-PN2 studies presented at EADV 2025.

Pooled data support ruxolitinib cream for treating prurigo nodularis

23 Oct 2025

Ammoxetine for major depressive disorder clears phase II study

22 Oct 2025

In the treatment of patients with major depressive disorder (MDD), ammoxetine is well tolerated and shows superior efficacy relative to placebo, as shown in a phase II study conducted in China.

Ammoxetine for major depressive disorder clears phase II study

22 Oct 2025

Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo

22 Oct 2025 by

Treatment with the Janus kinase (JAK) 1 inhibitor povorcitinib results in significant repigmentation of the body and face in adult patients with extensive nonsegmental vitiligo (NSV), with an acceptable safety profile, through 52 weeks, reports a phase II study.

Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo

22 Oct 2025

Adjuvant cemiplimab prolongs DFS in cutaneous SCC

22 Oct 2025 by

In the phase III C-POST trial, adjuvant cemiplimab prolongs disease-free survival (DFS) in individuals at high risk for recurrence of cutaneous squamous cell carcinoma (cSCC).

Adjuvant cemiplimab prolongs DFS in cutaneous SCC

22 Oct 2025

Ensitrelvir a viable alternative to available antivirals for COVID-19

21 Oct 2025 by

The investigational oral antiviral ensitrelvir shows potent antiviral activity in COVID-19, although its effect is slightly weaker than that of ritonavir-boosted nirmatrelvir, according to the ongoing, phase II, randomized controlled, adaptive pharmacometric platform PLATCOV trial.

Ensitrelvir a viable alternative to available antivirals for COVID-19

21 Oct 2025

Early IL-17 inhibitor use tied to quick response in psoriasis

21 Oct 2025

Early treatment with interleukin (IL)-17 inhibitors accelerates response and fosters disease modification in patients with psoriasis, reveals a study.

Early IL-17 inhibitor use tied to quick response in psoriasis

21 Oct 2025

Budesonide–formoterol reliever combo superior to salbutamol alone for mild asthma in kids

20 Oct 2025

The combination of inhaled corticosteroid budesonide plus formoterol appears to work better than the short-acting β2-agonist (SABA) salbutamol alone as reliever monotherapy for mild asthma in children, being associated with lower incidence of asthma attacks in a randomized controlled trial (RCT).

Budesonide–formoterol reliever combo superior to salbutamol alone for mild asthma in kids

20 Oct 2025

Trimetazidine lowers risk of stroke in presence of both IHD and AF

20 Oct 2025 by

Treatment with the antianginal agent trimetazidine appears to protect against the incidence of stroke and its recurrence in patients with both ischaemic heart disease (IHD) and atrial fibrillation (AF), as shown in a study from Hong Kong.

Trimetazidine lowers risk of stroke in presence of both IHD and AF

20 Oct 2025

Ceftriaxone 1 vs 2 g: Which dose leads to fewer clinical failure in bacteremia?

20 Oct 2025

The incidence of clinical failure does not differ between 1- and 2-g doses of ceftriaxone for the treatment of bacteremia, results of a study have shown.

Ceftriaxone 1 vs 2 g: Which dose leads to fewer clinical failure in bacteremia?

20 Oct 2025

News & Updates

Showing Pharmacy articles

Showing

Specialty:

PCV21 shows promise as alternative to PCV13 for infants

PCV21 shows promise as alternative to PCV13 for infants

Pooled data support ruxolitinib cream for treating prurigo nodularis

Pooled data support ruxolitinib cream for treating prurigo nodularis

Ammoxetine for major depressive disorder clears phase II study

Ammoxetine for major depressive disorder clears phase II study

Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo

Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo

Adjuvant cemiplimab prolongs DFS in cutaneous SCC

Adjuvant cemiplimab prolongs DFS in cutaneous SCC

Ensitrelvir a viable alternative to available antivirals for COVID-19

Ensitrelvir a viable alternative to available antivirals for COVID-19

Early IL-17 inhibitor use tied to quick response in psoriasis

Early IL-17 inhibitor use tied to quick response in psoriasis

Budesonide–formoterol reliever combo superior to salbutamol alone for mild asthma in kids

Budesonide–formoterol reliever combo superior to salbutamol alone for mild asthma in kids

Trimetazidine lowers risk of stroke in presence of both IHD and AF

Trimetazidine lowers risk of stroke in presence of both IHD and AF

Ceftriaxone 1 vs 2 g: Which dose leads to fewer clinical failure in bacteremia?

Ceftriaxone 1 vs 2 g: Which dose leads to fewer clinical failure in bacteremia?